Amneal Pharmaceuticals Operating Income Over Time
| AMRX Stock | USD 14.50 0.10 0.68% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Amneal Pharmaceuticals Performance and Amneal Pharmaceuticals Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amneal Pharmaceuticals. If investors know Amneal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Amneal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.61 | Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth 0.117 | Return On Assets |
Understanding Amneal Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Amneal's accounting equity. The concept of intrinsic value - what Amneal Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Amneal Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Amneal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amneal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Amneal Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Amneal Pharmaceuticals and related stocks such as Lantheus Holdings, Supernus Pharmaceuticals, and Indivior PLC Ordinary Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LNTH | (17.3 M) | (17.3 M) | (750 K) | (18.9 M) | 39.4 M | 42.5 M | 56.6 M | 51.9 M | 64.5 M | 51.7 M | (4.2 M) | (60.8 M) | 36.2 M | 364.6 M | 457 M | 525.5 M | 551.8 M |
| SUPN | (19 M) | (37.8 M) | (42.2 M) | (61.9 M) | 24.2 M | 17.7 M | 54.2 M | 99.5 M | 144.4 M | 148.6 M | 173.7 M | 86 M | 46.1 M | (5.3 M) | 81.7 M | 93.9 M | 98.6 M |
| INDV | 337.9 M | 337.9 M | 337.9 M | 337.9 M | 337.9 M | 337.9 M | 337.9 M | 423.3 M | 317.1 M | 178 M | (156 M) | 213 M | (81 M) | (156 M) | 32 M | 28.8 M | 27.4 M |
| TLX | (578 K) | (35.4 K) | (1.9 M) | (1.9 M) | (5.1 M) | (116 K) | (30 K) | (6.4 M) | (15.7 M) | (40.3 M) | (49.3 M) | (81.2 M) | (91.9 M) | 51.9 M | 82.1 M | 73.9 M | 77.6 M |
| PRGO | 53.9 M | 569.2 M | 679.1 M | 401.2 M | 567 M | 747.6 M | (2 B) | 598.2 M | 236.5 M | 174.7 M | 265.2 M | 410.4 M | 78.9 M | 151.9 M | 112.9 M | 129.8 M | 157.9 M |
| SLNO | (3.6 M) | (3.6 M) | (3.6 M) | (846.8 K) | (5.2 M) | (12.2 M) | (13.6 M) | (12.2 M) | (14.3 M) | (23.2 M) | (31.9 M) | (31.5 M) | (24.4 M) | (41.4 M) | (187.7 M) | (168.9 M) | (160.5 M) |
| MIRM | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (54.7 M) | (104.3 M) | (173.4 M) | (131.2 M) | (109.2 M) | (87.6 M) | (78.8 M) | (82.8 M) |
| NVST | 350 M | 350 M | 350 M | 350 M | 350 M | 350 M | 402.8 M | 386.6 M | 298.4 M | 235.7 M | 43.5 M | 306.2 M | 319.2 M | 31.5 M | (1 B) | 225.7 M | 113.6 M |
| BHC | (200 K) | 525.3 M | 79.7 M | (409.5 M) | 2 B | 1.5 B | (566 M) | 102 M | (2.4 B) | (203 M) | 676 M | 450 M | 454 M | 963 M | 1.5 B | 1.8 B | 1.9 B |
| DYN | 605 M | (236 M) | 714 M | (318 M) | (318 M) | 64 M | (640 M) | (412 M) | (4.8 M) | (13.8 M) | (58.6 M) | (150 M) | (171 M) | (242.2 M) | (343.9 M) | (309.5 M) | (294 M) |
Amneal Pharmaceuticals and related stocks such as Lantheus Holdings, Supernus Pharmaceuticals, and Indivior PLC Ordinary Operating Income description
Operating Income is the amount of profit realized from Amneal Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amneal Pharmaceuticals Class is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Amneal Pharmaceuticals Class | AMRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 400 Crossing Boulevard, |
| Exchange | NASDAQ Exchange |
USD 14.5
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals' price analysis, check to measure Amneal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals is operating at the current time. Most of Amneal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.